The COPD Assessment Test

These two brief webcasts provide background to the COPD Assessment Test (CAT)—a short, simple, validated questionnaire for measuring health status in COPD patients. The CAT can be used alongside measures such as lung function to give a more complete picture of how COPD affects a patient.

By using the CAT patients should be better able to describe the impact COPD has on them. Healthcare professionals should then have greater patient insight to support optimisation of patient care.

Introduction to the COPD Assessment Test

• This webcast contains an introduction to the COPD Assessment Test (CAT) as a validated tool to improve COPD consultations and why it was developed, presented by Professor David Price, Primary Care Respiratory Society UK, Professor of Primary Care Respiratory Medicine at the University of Aberdeen.

• Click here to view this webcast

Practical use of the COPD Assessment Test in clinical practice

• This webcast contains practical guidance on how the COPD Assessment Test (CAT) has been used in COPD consultations to the best effect, presented by Ms Vicki Knowles, Respiratory Clinical Lead, Surrey Community Health (SW Locality).

• Click here to view this webcast

At the end of each webcast you will be able to print out a certificate, which will provide you with evidence of your learning.

UK/CPD/0037/10. September 2010
The above mentioned webcasts were developed by MGP Ltd and funded by Allen & Hanburys, the Specialist Respiratory Division of GlaxoSmithKline UK. Allen & Hanburys had no editorial input other than reviewing the material for scientific accuracy and ABPI code compliance. The development of the COPD Assessment Test was funded by GlaxoSmithKline. COPD Assessment Test and the CAT logo are trademarks of the GlaxoSmithKline group of companies. © 2010 GlaxoSmithKline. All rights reserved.
No part of this publication may be reproduced in any form without the permission of MGP Ltd.

---

Implementing the NICE depression guideline

In summer 2010, Guidelines ran a series of workshops on implementing the updated NICE depression guideline at various locations around the country. The workshop series and subsequent webcasts were commissioned and sponsored by Lundbeck Ltd.

These three brief webcasts, filmed at the London workshop, will provide background on the updated NICE depression guideline and an insight into its implementation. The areas covered are:

• An overview of the NICE depression guideline, including changes to the guidance, and how it will impact on clinical practice
  Click here to view this webcast
• A review of the clinical evidence considered by NICE, including justification of prescribing choices/changes
  Click here to view this webcast
• Case studies that indicate how to achieve maximum QOF points for depression
  Click here to view this webcast

At the end of each webcast you can print off a certificate, which will provide you with evidence of your learning.

The webcasts were commissioned by and made possible through sponsorship by Lundbeck Ltd, which covered the facilities and costs incurred by MGP. Lundbeck Ltd were able to comment on the brief and reviewed the content for technical accuracy in order to comply with the requirements of the ABPI code of practice. The webcasts represent the opinions of the contributors themselves and do not necessarily represent the views of Lundbeck Ltd.
The workshops were financially supported by an educational grant from Lundbeck Ltd. Lundbeck Ltd had no input into the content of the meetings. However, Lundbeck Ltd reviewed the content of the workshops for technical accuracy and compliance with the ABPI Code of Practice.

UK/ESC/1007/0006b

Date of preparation: October 2010

---